2030年急性呼吸窘迫综合征(Ards)治疗市场规模

Global Acute Respiratory Distress Syndrome Ards Treatment Market

市场规模（十亿美元）

CAGR : 10.60 %

Forecast Period	2024 –2030
Market Size (Base Year)	USD MILLION Request
Market Size (Forecast Year)	USD 9,954,720.47
CAGR	10.60 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

全球急性呼吸窘迫综合征 (ARDS) 治疗市场，按类型（机械通气、皮质类固醇、抗病毒药物、体外膜氧合 (ECMO)、托珠单抗等）、病因（败血症、吸入有害物质、严重肺炎等）、给药途径（口服、肠外等）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、医院药房、零售药房和网上药房）划分 - 行业趋势和预测到 2030 年。

急性呼吸窘迫综合征 (ARDS) 治疗市场分析和规模

急性呼吸窘迫综合征等传染病和呼吸道疾病的日益流行，以及人们对疫苗开发以及针对这些疾病的治疗和诊断产品的广泛关注，增强了市场需求。技术进步使产品供应更加便捷，制造设施更加快速，也促进了市场增长。主要市场参与者高度关注产品发布和产品。

Data Bridge Market Research 分析，全球急性呼吸窘迫综合征 (ARDS) 治疗市场预计到 2030 年将达到 9,954,720.47 千美元，预测期内（2023-2030 年）的复合年增长率为 10.6%。本市场报告还深入介绍了定价分析和技术进步。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021（可定制为 2015 - 2020）
定量单位	收入（千美元）、销量（单位）、定价（美元）
涵盖的领域	类型（机械通气、皮质类固醇、抗病毒药物、体外膜氧合(ECMO)、托珠单抗等）、病因（败血症、吸入有害物质、重症肺炎等）、给药途径（口服、肠胃外等）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、医院药房、零售药房和网上药房）
覆盖国家	美国、加拿大、墨西哥、德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士、欧洲其他地区、日本、中国、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、科威特、以色列、中东和非洲其他地区
涵盖的市场参与者	Gilead Sciences, Inc.、Terumo Medical Corporation、Getting、LivaNova PLC、Medtronic、ResMed、Fisher & Paykel Healthcare Limited、Drägerwerk AG & Co. KGaA、NIPRO、Fresenius SE & Co. KGaA、Hamilton Medical、Pfizer Inc.、WEINMANN Emergency Medical Technology GmbH + Co. KG、EUROSETS、Armstrong Medical、Nice Neotech Medical Systems Pvt. Ltd. 和 Besmed Health Business Corp. 等

急性呼吸窘迫综合征 (ARDS) 治疗市场定义

急性呼吸窘迫综合征 (ARDS) 是一种危及生命的肺部损伤，会导致液体渗入肺部。大多数患有 ARDS 的人都会因创伤或 COVID-19 等疾病住院。这种综合征通常发生在肺部微小的弹性气囊（称为肺泡）中积液时。这种液体积聚会导致血液中的氧气减少。这会使器官无法获得足够的氧气来维持正常功能。患有其他疾病的人在诱发损伤或感染后几小时到几天内会患上 ARDS。死亡风险会随着年龄的增长而增加，并且根据疾病的严重程度，从该综合征中幸存下来会变得困难。

急性呼吸窘迫综合征 (ARDS) 治疗市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

司机

急性肺损伤患病率和发病率不断上升

由于人口老龄化、败血症和肺炎患者人数增加等多种因素，急性肺损伤患者被广泛报道。然而，大多数人直到晚期才被诊断出患有肺损伤和急性呼吸窘迫综合征。这种疾病是一种快速进展的疾病，发生在肺部受损的患者身上，导致体液泄漏。

近年来，由于各种引起呼吸道疾病的病毒的出现，急性呼吸窘迫综合征和肺损伤的病例不断增加。

普遍饮酒的人数也很多，进一步增加了疾病的负担。因此，无论年龄大小，增加饮酒量都会导致 ARDS 等症状。其他风险因素，如呼吸困难、高血压、糖尿病等，都会导致 ARDS 的发展。与急性呼吸窘迫综合征相关的各种风险因素增加了发展临床症状的可能性，同时也增加了疾病的病例。这些积极的风险因素预计将推动市场增长。

机会

医疗支出增加，改善治疗设施

随着各国人口的可支配收入增加，全球医疗支出也随之增加。此外，为了满足人口需求，政府机构和医疗组织正在采取主动行动，加快医疗支出。医疗支出的增加同时有助于医疗机构改善其急性呼吸窘迫综合征的治疗设施，因为这种疾病近年来非常普遍。

医疗支出的增长也有利于进一步的经济增长和医疗保健行业的增长，而且它的主要成果是，它显著影响了呼吸机和其他 ARDS 治疗设备等更好、更先进的治疗方案的开发。因此，预计医疗支出的激增将为市场增长创造机会。

克制/挑战

设备和治疗费用高昂

重症监护和重症监护病房服务的使用率在世界范围内不断增长，其昂贵的费用是当前医疗保健系统的主要问题。然而，急性呼吸窘迫综合征正在获得广泛的先进治疗选择，而长期治疗的费用对于中等收入人群来说相当难以负担。ARDS 患者通常需要长期住院，频繁使用货币化和呼吸机，消耗大量医疗资源。因此，大多数无法负担长期住院费用的患者在治疗初期就出院了。然而，这增加了新感染并发症的可能性和易感性，这需要额外的医疗资源和治疗。

最新动态

2023 年 7 月，ResMed 宣布收购美国睡眠和呼吸护理诊断软件领域的领导者 Somnoware。此次收购有助于该组织创造更多收入。
2022 年 10 月，NIPRO 宣布其合并子公司之一 Nipro Asia Pte. Ltd. 在菲律宾共和国成立了一家医疗器械销售子公司——Nipro Medical Philippines Corp.。这有助于该组织创造更多收入。
2021 年 11 月，Fisher & Paykel Healthcare Limited 宣布推出用于无创通气的 F&P Visairo 医院鼻下面罩。F&P Visairo 是一款采用动态支撑技术的新型高性能鼻下医院面罩。这可以实现无鼻梁无创通气，消除鼻梁压力，为开阔视野扫清障碍，同时又不影响稳定性和性能。这有助于公司扩大其产品组合。
2021 年 4 月，汉密尔顿医疗公司宣布推出了具有多种功能的新型 HAMILTON-C1/T1/MR1 呼吸机，包括 CPR 通气、升级的高流量氧气治疗、容量支持模式和呼吸护理数字解决方案。这有助于该公司提高其在全球市场的影响力并增加收入。
2021 年 2 月，辉瑞 CentreOne 宣布推出新的 API 和中间体活动。该活动专注于为药品开发商和制造商提供全面的复杂 API 化合物和中间体。此次活动的推出帮助该公司进入市场。

急性呼吸窘迫综合征 (ARDS) 治疗市场范围

全球急性呼吸窘迫综合征 (ARDS) 治疗市场根据类型、原因、给药途径、最终用户和分销渠道分为五个部分。这些部分之间的增长将帮助您分析行业中增长微弱的部分，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

机械通气
皮质类固醇
抗病毒药物
体外膜氧合 (ECMO)
托珠单抗
其他的

根据类型，市场分为机械通气、皮质类固醇、抗病毒药物、体外膜氧合 (ECMO)、托珠单抗等。

原因

脓毒症
吸入有害物质
严重肺炎
其他的

根据病因，市场分为败血症、吸入有害物质、严重肺炎等。

给药途径

口服
父母
其他的

根据给药途径，市场分为口服、肠外和其他。

最终用户

医院
家庭医疗保健
专科诊所
其他的

根据最终用户，市场分为医院、专科诊所、家庭医疗保健和其他。

分销渠道

直接招标
医院药房
网上药店
零售药店

根据分销渠道，市场分为直接招标、医院药房、零售药房和网上药房。

区域分析/见解：急性呼吸窘迫综合征 (ARDS) 治疗市场

对全球急性呼吸窘迫综合征 (ARDS) 治疗市场进行了分析，并按国家、类型、原因、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。

本全球急性呼吸窘迫综合征 (ARDS) 治疗市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士、欧洲其他地区、日本、中国、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、科威特、以色列以及中东和非洲其他地区。

由于意识和筛查的不断提高以及医疗支出的不断增加，美国预计将以最大的市场份额主导北美地区。由于急性呼吸窘迫综合征的患病率不断上升以及新技术进步的渗透，德国预计将主导欧洲地区。由于研发活动的不断增加以及患者倾向于个性化治疗，日本预计将主导亚太地区。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。

急性呼吸窘迫综合征 (ARDS) 治疗市场竞争格局和份额分析

全球急性呼吸窘迫综合征 (ARDS) 治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

全球急性呼吸窘迫综合征 (ARDS) 治疗市场的一些主要市场参与者包括 Gilead Sciences, Inc.、Terumo Medical Corporation、Getting、LivaNova PLC、Medtronic、ResMed、Fisher & Paykel Healthcare Limited、Drägerwerk AG & Co. KGaA、NIPRO、Fresenius SE & Co. KGaA、Hamilton Medical、Pfizer Inc.、WEINMANN Emergency Medical Technology GmbH + Co. KG、EUROSETS、Armstrong Medical、nice Neotech Medical Systems Pvt. Ltd. 和 Besmed Health Business Corp. 等。

SKU-70275

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT

TABLE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 6 GLOBAL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 7 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 10 GLOBAL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 11 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 12 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 14 GLOBAL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 15 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 GLOBAL TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 19 GLOBAL SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 GLOBAL INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 GLOBAL SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 24 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 GLOBAL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 26 GLOBAL ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 29 GLOBAL HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 30 GLOBAL SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 GLOBAL HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 GLOBAL OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 34 GLOBAL DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 GLOBAL HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 GLOBAL RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 37 GLOBAL ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 40 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 43 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 45 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 46 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 47 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 48 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 49 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 50 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 51 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 52 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 55 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 56 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 57 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 58 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 59 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 61 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 62 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 63 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 64 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 65 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 66 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 68 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 70 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 71 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 72 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 73 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 74 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 76 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 77 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 78 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 79 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 80 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 81 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 82 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 83 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 85 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 86 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 88 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 89 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 91 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 92 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 93 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 94 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 96 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 97 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 98 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 99 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 101 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 103 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 104 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 105 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 106 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 107 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 108 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 109 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 110 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 113 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 114 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 116 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 117 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 119 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 120 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 121 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 122 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 123 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 124 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 125 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 126 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 127 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 128 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 129 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 131 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 132 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 134 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 135 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 136 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 137 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 138 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 139 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 140 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 142 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 143 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 144 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 146 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 147 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 149 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 150 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 151 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 152 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 153 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 154 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 155 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 158 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 159 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 161 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 162 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 163 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 164 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 165 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 166 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 167 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 168 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 169 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 170 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 173 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 174 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 175 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 176 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 177 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 179 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 180 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 181 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 182 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 183 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 184 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 185 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 188 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 189 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 191 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 192 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 194 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 195 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 196 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 197 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 198 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 199 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 200 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 201 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 202 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 203 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 204 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 206 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 207 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 209 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 210 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 211 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 212 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 213 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 214 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 215 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 217 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 218 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 219 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 221 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 222 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 223 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 224 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 225 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 226 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 227 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 228 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 229 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 230 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 232 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 233 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 234 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 236 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 237 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 238 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 239 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 240 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 241 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 242 BELGIUM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 243 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 244 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 245 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 248 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 249 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 251 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 252 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 253 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 254 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 255 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 256 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 257 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 258 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 259 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 260 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 262 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 263 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 265 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 267 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 268 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 269 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 270 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 271 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 272 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 273 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 275 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 277 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 278 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 279 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 280 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 281 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 283 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 284 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 285 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 287 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 288 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 289 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 290 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 291 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 292 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 293 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 294 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 295 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 296 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 297 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 298 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 299 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 300 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 301 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 302 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 303 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 304 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 305 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 306 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 307 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 308 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 310 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 311 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 313 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 314 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 315 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 316 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 317 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 318 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 319 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 320 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 321 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 322 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 323 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 324 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 325 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 326 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 327 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 328 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 329 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 330 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 331 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 332 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 333 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 334 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 335 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 336 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 337 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 338 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 339 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 340 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 341 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 342 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 343 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 344 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 345 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 346 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 347 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 348 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 349 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 350 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 351 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 352 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 353 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 354 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 355 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 356 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 357 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 358 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 359 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 360 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 361 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 362 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 363 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 364 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 365 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 366 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 367 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 368 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 369 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 370 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 371 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 372 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 373 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 374 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 375 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 376 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 377 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 378 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 379 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 381 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 382 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 383 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 384 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 385 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 386 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 387 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 388 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 389 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 390 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 391 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 392 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 393 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 394 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 395 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 396 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 397 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 398 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 399 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 400 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 401 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 402 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 403 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 404 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 405 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 406 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 407 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 408 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 409 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 411 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 412 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 413 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 414 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 415 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 416 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 417 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 418 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 419 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 420 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 421 PHILIPPINES PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 422 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 423 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 424 REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 425 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 426 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 427 SOUTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 428 SOUTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 429 SOUTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 430 SOUTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 431 SOUTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 432 SOUTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 433 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 434 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 435 SOUTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 436 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 437 SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 438 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 439 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 440 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 441 BRAZIL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 442 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 443 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 444 BRAZIL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 445 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 447 BRAZIL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 448 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 449 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 450 BRAZIL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 451 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 452 BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 453 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 454 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 455 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 456 ARGENTINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 457 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 458 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 459 ARGENTINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 460 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 461 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 462 ARGENTINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 463 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 464 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 465 ARGENTINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 466 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 467 ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 468 REST OF SOUTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 469 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 470 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 471 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 472 MIDDLE EAST AND AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 473 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 474 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 475 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 476 MIDDLE EAST AND AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 477 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 478 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 479 MIDDLE EAST AND AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 480 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 481 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 482 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 483 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 484 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 485 SOUTH AFRICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 486 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 487 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 488 SOUTH AFRICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 489 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 490 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 491 SOUTH AFRICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 492 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 493 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 494 SOUTH AFRICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 495 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 496 SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 497 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 498 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 499 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 500 SAUDI ARABIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 501 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 502 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 503 SAUDI ARABIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 504 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 505 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 506 SAUDI ARABIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 507 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 508 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 509 SAUDI ARABIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 510 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 511 SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 512 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 513 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 514 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 515 U.A.E MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 516 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 517 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 518 U.A.E CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 519 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 520 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 521 U.A.E ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 522 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 523 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 524 U.A.E PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 525 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 526 U.A.E ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 527 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 528 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 529 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 530 ISRAEL MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 531 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 532 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 533 ISRAEL CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 534 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 535 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 536 ISRAEL ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 537 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 538 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 539 ISRAEL PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 540 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 541 ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 542 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 543 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 544 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 545 EGYPT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 546 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 547 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 548 EGYPT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 549 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 550 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 551 EGYPT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 552 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 553 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 554 EGYPT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 555 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 556 EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 557 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 558 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 559 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 560 KUWAIT MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 561 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 562 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 563 KUWAIT CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 564 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 565 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME)

TABLE 566 KUWAIT ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 567 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND)

TABLE 568 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 569 KUWAIT PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 570 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 571 KUWAIT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 572 REST OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

图片列表

FIGURE 1 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 2 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030

FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET

FIGURE 14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022

FIGURE 15 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 16 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 17 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022

FIGURE 19 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND)

FIGURE 20 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 21 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 22 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 23 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 24 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 25 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022

FIGURE 27 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 28 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 31 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 32 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 33 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 35 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 36 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

How big is the Acute Respiratory Distress Syndrome (ARDS) Treatment Market?

The Acute Respiratory Distress Syndrome (ARDS) Treatment Market will be worth USD 9,954,720.47 thousand by 2030.

What is the growth rate of the Acute Respiratory Distress Syndrome (ARDS) Treatment Market?

The Acute Respiratory Distress Syndrome (ARDS) Treatment Market growth rate is 10.6% during the forecast period.

What are the growth drivers of the Acute Respiratory Distress Syndrome (ARDS) Treatment Market?

Increasing Prevalence and Incidence of Acute Lung Injury are the growth drivers of the Acute Respiratory Distress Syndrome (ARDS) Treatment Market.

What are the factors on which the Acute Respiratory Distress Syndrome (ARDS) Treatment Market research is based on?

The type, cause, route of administration, end user, and distribution channel are the factors on which the Acute Respiratory Distress Syndrome (ARDS) Treatment Market research is based.

Which are the major companies in the Acute Respiratory Distress Syndrome (ARDS) Treatment Market?

ResMed announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software & NIPRO announced that one of its consolidated subsidiaries, Nipro Asia Pte. Ltd., had established a medical device sales subsidiary—Nipro Medical Philippines Corp., in the Republic of the Philippines are the major companies in the Acute Respiratory Distress Syndrome (ARDS) Treatment Market.

全球急性呼吸窘迫综合征 (ARDS) 治疗市场 – 行业趋势和 2030 年预测

全球急性呼吸窘迫综合征 (ARDS) 治疗市场 – 行业趋势和 2030 年预测

Global Acute Respiratory Distress Syndrome Ards Treatment Market

CAGR : 10.60 %

急性呼吸窘迫综合征 (ARDS) 治疗市场分析和规模

急性呼吸窘迫综合征 (ARDS) 治疗市场定义

急性呼吸窘迫综合征 (ARDS) 治疗市场动态

急性呼吸窘迫综合征 (ARDS) 治疗市场范围

区域分析/见解：急性呼吸窘迫综合征 (ARDS) 治疗市场

急性呼吸窘迫综合征 (ARDS) 治疗市场竞争格局和份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

全球急性呼吸窘迫综合征 (ARDS) 治疗市场 – 行业趋势和 2030 年预测

全球急性呼吸窘迫综合征 (ARDS) 治疗市场 – 行业趋势和 2030 年预测

Global Acute Respiratory Distress Syndrome Ards Treatment Market

CAGR : 10.60 %

急性呼吸窘迫综合征 (ARDS) 治疗市场分析和规模

急性呼吸窘迫综合征 (ARDS) 治疗市场定义

急性呼吸窘迫综合征 (ARDS) 治疗市场动态

急性呼吸窘迫综合征 (ARDS) 治疗市场范围

区域分析/见解：急性呼吸窘迫综合征 (ARDS) 治疗市场

急性呼吸窘迫综合征 (ARDS) 治疗市场竞争格局和份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面